Fulcrum Therapeutics Files 2024 10-K
Ticker: FULC · Form: 10-K · Filed: Feb 25, 2025 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 10-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceutical, annual-report
TL;DR
Fulcrum Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Fulcrum Therapeutics, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is incorporated in Delaware and headquartered in Cambridge, MA. Key financial data and operational details for the fiscal year are presented in this comprehensive report.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Fulcrum Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Fulcrum Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 2025-02-25 — Filing Date (The 10-K was filed on this date.)
- 001-38978 — SEC File Number (The company's SEC file number.)
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-25 (date) — Filing date
- Cambridge, MA (location) — Company headquarters
- 26 Landsdowne Street (location) — Company business and mail address
- Losmapimod (drug) — Mentioned in relation to operating segments
- Ra Capital (company) — Mentioned with a date of 2024-08-31
FAQ
What is Fulcrum Therapeutics' primary business focus?
Fulcrum Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
When did Fulcrum Therapeutics' fiscal year 2024 end?
The Conformed Period of Report for this 10-K is 20241231, meaning the fiscal year ended on December 31, 2024.
Where is Fulcrum Therapeutics headquartered?
The company's business address is listed as 26 Landsdowne Street, Cambridge, MA 02139.
What is the company's SEC file number?
Fulcrum Therapeutics' SEC file number is 001-38978.
What specific drug is mentioned in the filing context?
The drug Losmapimod is mentioned in relation to operating segments and the fiscal year 2023.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 25, 2025 regarding Fulcrum Therapeutics, Inc. (FULC).